Notably, targeted inhibition of SphK2 exhibits more significant anticancer effects than SphK1 in various cancer cell lines, and gene knockout experiments have confirmed that the anticancer effect of SphK2 deletion is far superior to that of SphK1 or dual enzyme inhibition (48). This evidence concerns the gene SPHK1 and cancer.